Clinical Trial Update: Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

This entry reports the completion of a Phase 2 trial evaluating oral MKC-1 in unresectable or metastatic pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• MKC-1

Snippet

Sponsor: CASI Pharmaceuticals, Inc. | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED